RATIONALE: Screening tests, such as sputum cytology, may help doctors find tumor cells early and plan better treatment for lung cancer.

PURPOSE: This phase II trial is studying how well sputum cytology works in screening heavy smokers for lung cancer.

Condition	Treatment or Intervention	Phase
Non-small cell lung cancer Small Cell Lung Cancer	Procedure: annual screening  Procedure: cytologic sampling  Procedure: screening intervention  Procedure: study of high risk factors  Procedure: study of physiologic variables	Phase II

Further Study Details: 

OBJECTIVES: Primary

• Classify annual sputum samples cytologically in participants with or without airflow obstruction and a heavy smoking history.
• Correlate sputum cytological atypia (moderate atypia or worse) with lung cancer incidence in these participants.
• Correlate changes in sputum cytology (i.e., changes toward higher grades of atypia) with lung cancer incidence in these participants.

Secondary

• Determine other risk factors for lung cancer (e.g., diet, family history, smoking history, and medications) that may either confound or modify the association between sputum cytology and lung cancer risk in these participants.

OUTLINE: Two 3-day pooled sputum samples are collected for 6 consecutive days from participants by the spontaneous cough technique for cytopathological evaluation. Participants also complete a risk factor questionnaire and undergo a pulmonary function test by spirometry and a blood draw.

Participants complete a questionnaire updating smoking, vital, and lung cancer status and undergo sputum sample collection annually.

Participants are informed of sputum cytology results.

PROJECTED ACCRUAL: A total of 3,400 participants (2,900 with airflow obstruction and 500 without airflow obstruction) will be accrued for this study.

Ages Eligible for Study:  25 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Current or ex-smoker with a lifetime history of cigarette smoking of ≥ 20 pack years, meeting 1 of the following criteria:
• Airflow obstruction
• FEV_1 < 75% predicted for age by spirometry
• FEV_1/FVC ≤ 75% by spirometry
• No airflow obstruction
• No history of lung cancer

PATIENT CHARACTERISTICS: Age

• 25 and over

Performance status

• Not specified

Life expectancy

• More than 5 years

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• No cancer within the past 5 years except nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Colorado
      University of Colorado Health Sciences Center - Denver, Denver,  Colorado,  80262,  United States; Recruiting

Study chairs or principal investigators

Timothy Kennedy,  Principal Investigator,  University of Colorado   

Study ID Numbers:  CDR0000382125; UCHSC-92-392; NCT00103363
Record last reviewed:  January 2005
Last Updated:  February 15, 2005
Record first received:  February 7, 2005
ClinicalTrials.gov Identifier:  NCT00103363
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08